Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The prospective, multicenter, single-arm design study is to evaluate the efficacy and safety
of fruquintinib for patients with advanced or metastatic biliary tract adenocarcinoma who
failed first-line chemotherapy with gemcitabine, platinum/S-1, and albumin paclitaxel.